Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · IEX Real-Time Price · USD
4.270
-0.040 (-0.93%)
At close: Jul 19, 2024, 4:00 PM
4.450
+0.180 (4.22%)
Pre-market: Jul 22, 2024, 8:34 AM EDT
Fate Therapeutics Employees
Fate Therapeutics had 181 employees as of December 31, 2023. The number of employees decreased by 370 or -67.15% compared to the previous year.
Employees
181
Change (1Y)
-370
Growth (1Y)
-67.15%
Revenue / Employee
$35,790
Profits / Employee
-$1,050,006
Market Cap
486.06M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Enhabit | 10,800 |
Treace Medical Concepts | 516 |
Jin Medical International | 245 |
biote | 194 |
Heron Therapeutics | 126 |
Theravance Biopharma | 99 |
Oculis Holding AG | 36 |
Third Harmonic Bio | 30 |
FATE News
- 19 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm - PRNewsWire
- 7 weeks ago - Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program - GlobeNewsWire
- 2 months ago - Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting - GlobeNewsWire
- 3 months ago - Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting - GlobeNewsWire
- 3 months ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire